EP2015782A4 - Compositions and methods for modulating gene expression - Google Patents
Compositions and methods for modulating gene expressionInfo
- Publication number
- EP2015782A4 EP2015782A4 EP07760600A EP07760600A EP2015782A4 EP 2015782 A4 EP2015782 A4 EP 2015782A4 EP 07760600 A EP07760600 A EP 07760600A EP 07760600 A EP07760600 A EP 07760600A EP 2015782 A4 EP2015782 A4 EP 2015782A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- methods
- gene expression
- modulating gene
- modulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79130506P | 2006-04-12 | 2006-04-12 | |
PCT/US2007/066571 WO2007121326A2 (en) | 2006-04-12 | 2007-04-12 | Compositions and methods for modulating gene expression |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2015782A2 EP2015782A2 (en) | 2009-01-21 |
EP2015782A4 true EP2015782A4 (en) | 2010-04-07 |
Family
ID=38610393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07760600A Withdrawn EP2015782A4 (en) | 2006-04-12 | 2007-04-12 | Compositions and methods for modulating gene expression |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2015782A4 (en) |
CA (1) | CA2649114A1 (en) |
WO (1) | WO2007121326A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2784829T3 (en) | 2009-04-08 | 2020-10-01 | Faulstich Heinz Dr | Amatoxin-provided therapeutic cell surface-binding components designed for tumor therapy |
ES2402254T3 (en) * | 2010-09-30 | 2013-04-30 | Heidelberg Pharma Ag | Amatoxin conjugates with improved linkers |
US9815877B2 (en) | 2012-06-07 | 2017-11-14 | The Children's Hospital Of Philadelphia | Controlled gene expression methods |
EP2774624A1 (en) * | 2013-03-04 | 2014-09-10 | Heidelberg Pharma GmbH | Amatoxin derivatives |
JP6321687B2 (en) * | 2014-03-10 | 2018-05-09 | ハイデルベルク ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Amatoxin derivatives |
IL303455A (en) | 2016-06-17 | 2023-08-01 | Crispr Therapeutics Ag | Compositions and methods for the depletion of cd117+cells |
EP3738608A4 (en) * | 2017-08-18 | 2021-12-08 | Sichuan Baili Pharm Co. Ltd | Non-natural amatoxin-type antibody conjugate |
WO2024036143A2 (en) * | 2022-08-09 | 2024-02-15 | Ptc Therapeutics, Inc. | Methods for modulating rna splicing |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030105045A1 (en) * | 2000-10-13 | 2003-06-05 | Crosslink Genetics Corporation | Artificial transcriptional factors and methods of use |
-
2007
- 2007-04-12 EP EP07760600A patent/EP2015782A4/en not_active Withdrawn
- 2007-04-12 WO PCT/US2007/066571 patent/WO2007121326A2/en active Application Filing
- 2007-04-12 CA CA002649114A patent/CA2649114A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030105045A1 (en) * | 2000-10-13 | 2003-06-05 | Crosslink Genetics Corporation | Artificial transcriptional factors and methods of use |
Non-Patent Citations (6)
Title |
---|
ANSARI A Z ET AL: "TOWARDS A MINIMAL MOTIF FOR ARTIFICIAL TRANSCRIPTIONAL ACTIVATORS", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 8, no. 6, 1 January 2001 (2001-01-01), pages 583 - 592, XP001031162, ISSN: 1074-5521 * |
ARORA PARAMJIT S ET AL: "Design of artificial transcriptional activators with rigid poly-L-proline linkers.", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 124, no. 44, 6 November 2002 (2002-11-06), pages 13067 - 13071, XP007911805, ISSN: 0002-7863 * |
INGLES C J ET AL: "ALPHA AMANITIN RESISTANCE OF RNA POLYMERASE II IN MUTANT CHINESE HAMSTER OVARY CELL LINES", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 251, no. 9, 1976, pages 2729 - 2734, XP007911801, ISSN: 0021-9258 * |
KUZNETSOVA S ET AL: "Gene activation by triplex-forming oligonucleotide coupled to the activating domain of protein VP16", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 27, no. 20, 15 October 1999 (1999-10-15), pages 3995 - 4000, XP002222219, ISSN: 0305-1048 * |
KWON YOUNGJOO ET AL: "Small molecule transcription factor mimic", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 126, no. 49, 15 December 2004 (2004-12-15), pages 15940 - 15941, XP007911804, ISSN: 0002-7863 * |
STANOJEVIC D ET AL: "A highly potent artificial transcription factor", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON, PA.; US, vol. 41, no. 23, 11 June 2002 (2002-06-11), pages 7209 - 7216, XP002222221, ISSN: 0006-2960 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007121326A2 (en) | 2007-10-25 |
EP2015782A2 (en) | 2009-01-21 |
CA2649114A1 (en) | 2007-10-25 |
WO2007121326A3 (en) | 2008-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200908481B (en) | Compositions and methods for altering gene expression | |
IL250678A0 (en) | Compositions and methods for inhibiting expression of the pcsk9 gene | |
EP2052085A4 (en) | Methods for modulating set and uses thereof | |
IL195619A0 (en) | Compositions and methods for joininig non-conjoined iumens | |
HK1137670A1 (en) | Compositions and methods for arthrodetic procedures | |
IL194788A0 (en) | Compositions and methods for modulating vascular development | |
EP2068875A4 (en) | Compositions and methods for modulating sirtuin activity | |
EP2043696A4 (en) | Methods and compositions for targeting gc1qr/p32 | |
IL202184A0 (en) | Methods and compositions for increased transgene expression | |
EP2066687A4 (en) | Compositions and methods for inhibiting expression of the hamp gene | |
IL194814A0 (en) | Mglur5 modulators i | |
PT2129680E (en) | Combined hairpin-antisense compositions and methods for modulating expression | |
EP2101731A4 (en) | Endoxifen methods and compositions | |
EP2235033A4 (en) | Methods and compositions for increasing gene expression | |
ZA200807714B (en) | Gene disruptions, compositions and methods relating thereto | |
EP2015782A4 (en) | Compositions and methods for modulating gene expression | |
EP2088865A4 (en) | Guggulphospholipid methods and compositions | |
AU2007291030A8 (en) | Novel compositions and methods | |
ZA200808498B (en) | Novel gene disruptions,compositions and methods relating thereto | |
EP2018443A4 (en) | Compositions and methods for inhibiting expression of ikk-b gene | |
GB0610009D0 (en) | Culture medium | |
EP2142672A4 (en) | Compositions and methods for gene silencing | |
EP2132251A4 (en) | Composition and method | |
GB0625208D0 (en) | Composition and method | |
GB0600261D0 (en) | Composition and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20081112 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
R17D | Deferred search report published (corrected) |
Effective date: 20081224 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/00 20060101ALI20090120BHEP Ipc: A61K 38/00 20060101ALI20090120BHEP Ipc: C12Q 1/02 20060101ALI20090120BHEP Ipc: C12Q 1/68 20060101AFI20090120BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100304 |
|
17Q | First examination report despatched |
Effective date: 20100616 |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CROSSLINK GENETICS CORPORATION |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20140325 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20140805 |